Roquinimex
Grundinformationen
- CAS
84088-42-6- Standard-SMILES
CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1- InChIKey
SGOOQMRIPALTEL-UHFFFAOYSA-N- Summenformel
- C18H16N2O3
- Durchschnittliche Molmasse
- 308,3 g/mol
- Monoisotopische Masse
- 308,11609238
Überblick
4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide is an aromatic amide.
Namen und Bezeichner
- Bevorzugter Name
- Roquinimex
- IUPAC
- 4-hydroxy-N,1-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide
- Englischer Name
- Roquinimex
- Summenformel
- C18H16N2O3
- Molmasse
- 308.33
Namen und Synonyme
ROQUINIMEXLinomide84088-42-6LS-26164-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamideFCF 89LS 2616RoquinimexumFCF-89DTXSID40456801,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-3-quinolinecarboxanilide372T2944C0
Weitere Namen anzeigen
FCF89CS-1231ABR212616PNU 212616Roquinimex(Linomide)Roquinimex, 10 mM in DMSON,1-Dimethyl-N-phenyl-2-oxo-4-hydroxy-1,2-dihydroquinoline-3-carboxamide
DTXCID20256803-Quinolinecarboxamide, 1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl1,2-dihydro-4-hydroxy-n,1-dimethyl-2-oxo-n-phenyl-3-quinolinecarboxamideRefChem:8836963-Quinolinecarboxamide, 1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-N-phenylmethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamideL03AX02N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide
Datenbank-Bezeichner
- CAS
84088-42-6- PubChem CID
- 54676478
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 2,7
- Polarare Oberfläche (TPSA)
- 60,9 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 3
- Frei drehbare Bindungen
- 2
- Schwere Atome
- 23
- Formalladung
- 0
- Komplexität
- 522
Experimentelle und physikochemische Eigenschaften
DrugsPharmaceuticals -> Listed in ZINC15
Physikochemische Eigenschaften
- Schmelzpunkt
- 200 · 200-204°
- Siedepunkt
- 436.2 · 436.2±45.0 °C(Predicted)
- Dichte
- 1.357 · 1.357±0.06 g/cm3(Predicted)
- storage temp.
- 2 · Sealed in dry,2-8°C
- Löslichkeit
- 11 mg/mL · DMSO: 11 mg/mL
- Aggregatzustand
- solid
- pka
- 4.5 · 4.50±1.00(Predicted)
- Farbe
- White to off-white
- Merck
- 14 · 14,8259
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Danger
H301 (98.5%): Toxic if swallowed [Danger Acute toxicity, oral]
P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 67 reports by companies from 2 notifications to the ECHA C&L Inventory.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 3 (98.5%)
Sicherheitsdaten
- wgk
- 3
- ridadr
- UN 2811 6.1/PG 3
- hs_code
- 2933.49.2600
- risk_code
- 22
- hazard_code
- Xn
- safety_code
- 36/37
Chemie und Industrie
Pharmakologische Informationen
ATC Code
L - Antineoplastic and immunomodulating agents
QL - Antineoplastic and immunomodulating agents
Metabolism/Metabolites
Linomide has known human metabolites that include 4,7-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, 4,6-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, 4-hydroxy-N-(4-hydroxyphenyl)-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4,8-dihydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, 4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, and 4-hydroxy-N-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide.
MeSH Pharmacological Classification
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
Anwendungen
BeschreibungRoquinimex is an immunomodulator with diverse biological activities. In vivo, roquinimex (80 mg/kg) increases the number of myocardial MHC class II-expressing cells, the ratio of cytotoxic to helper T cells, and survival and decreases necrotic lesion area in a mouse model of murine coxsackievirus B3-induced myocarditis. It induces IFN-γ production, reduces TNF-α and IL-1β production, prevents the development of proteinuria, and ameliorates nephritis in a mouse model of chronic graft versus host disease (GVHD). Roquinimex (300 mg/kg) decreases colonic myeloperoxidase (MPO) activity and mucosal damage in a mouse model of colitis induced by dextran sulfate (DSS; ). It also decreases tumor weight and tumor blood flow in a von Hippel-Lindau (VHL) type 2a paraganglioma mouse xenograft model.
Zugehörige Reaktionen
1
Notizen zur Verbindung
Wird geladen…